SHANNON REPKA: Open Payments
NPI 1063634897 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$879 in 37 payments from 13 companies in 2025. Trend: 2023 $1,575 · 2024 $1,126 · 2025 $879
Food & beverage: $879
| Company | Payments | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | 5 | $120 |
| PFIZER INC. | 4 | $118 |
| Aimmune Therapeutics, Inc. | 5 | $116 |
| ABBVIE INC. | 3 | $93 |
| VERTEX PHARMACEUTICALS INCORPORATED | 4 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $79 |
| Ferring Pharmaceuticals Inc. | 2 | $66 |
| E.R. Squibb & Sons, L.L.C. | 2 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
| CSL Behring | 2 | $48 |
Products named: ULTOMIRIS, VYNDAQEL, VOWST, DALVANCE, JOURNAVX, XIFAXAN, REBYOTA, ELIQUIS.
Industry payments across TX — which companies pay providers there.
